Hepatic Clinical Trials

1 recruiting

Hepatic Trials at a Glance

200 actively recruiting trials for hepatic are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 55 trials, with the heaviest enrollment activity in San Antonio, Orlando, and Shanghai. Lead sponsors running hepatic studies include Fudan University, Mayo Clinic, and IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Treatments under study

About Hepatic Clinical Trials

Looking for clinical trials for Hepatic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 200 trials

Recruiting
Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea

Progressive Familial Intrahepatic Cholestasis
Ipsen10 enrolled3 locationsNCT07185919
Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting

A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain

PFIC - Progressive Familial Intrahepatic Cholestasis
Ipsen150 enrolled10 locationsNCT07191704
Recruiting
Phase 1

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Not Applicable

Early TIPS in Patients With Liver Cirrhosis and Ascites

Liver CirrhosisPortal HypertensionAscites Hepatic
University Hospital Freiburg134 enrolled1 locationNCT06576934
Recruiting
Phase 1

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

Hepatic Insufficiency
Boehringer Ingelheim44 enrolled3 locationsNCT06957756
Recruiting
Phase 1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

Hepatic CirrhosisLiver Fibrosis
AstraZeneca12 enrolled2 locationsNCT07069725
Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria
Alnylam Pharmaceuticals150 enrolled30 locationsNCT04883905
Recruiting
Phase 2

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Intrahepatic Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center164 enrolled11 locationsNCT04891289
Recruiting
Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

CholangiocarcinomaBile Duct CancerCholangiocarcinoma Non-resectable+2 more
Beth Israel Deaconess Medical Center30 enrolled1 locationNCT05655949
Recruiting
Phase 1

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 1Phase 2

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328
Recruiting
Not Applicable

Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis

Type 2 DiabetesHepatic Steatosis
AdventHealth Translational Research Institute12 enrolled1 locationNCT06993454
Recruiting
Not Applicable

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)

Liver AblationHepatic
M.D. Anderson Cancer Center50 enrolled1 locationNCT05361551
Recruiting
Phase 1

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Moderate Hepatic Impairment
AstraZeneca20 enrolled2 locationsNCT07343960
Recruiting
Phase 1

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Healthy Volunteer StudyRenal ImpairmentHepatic Impairment
Atea Pharmaceuticals, Inc.28 enrolled2 locationsNCT06911320
Recruiting
Phase 1

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting
Phase 4

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

CirrhosisAscitesPortal Vein Thrombosis+3 more
Asian Institute Of Medical Sciences220 enrolled1 locationNCT07521332